as 252424 profile

5-(5-(4-fluoro-2-hydroxyphenyl)furan-2-ylmethylene)thiazolidine-2,4-dione: a PI3K gamma inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	11630874
CHEMBL ID	379156
SCHEMBL ID	1494573
MeSH ID	M0500761

Synonym
as-252424 ,
(z)-5-((5-(4-fluoro-2-hydroxyphenyl)furan-2-yl)methylene)thiazolidine-2,4-dione
bdbm50189744
NCGC00185997-01
CHEMBL379156 ,
HMS3229L07
as252424 ,
900515-16-4
HMS3260O16
BCP9000324
as 252424
CCG-101298
(5z)-5-{[5-(4-fluoro-2-hydroxyphenyl)furan-2-yl]methylidene}-1,3-thiazolidine-2,4-dione
BCPP000387
LP00157
S2671
5-((5-(4-fluoro-2-hydroxyphenyl)-2-furanyl)methylene)-2,4-thiazolidinedione
HY-13532
CS-3164
63d4ruv1gn ,
unii-63d4ruv1gn
2,4-thiazolidinedione, 5-((5-(4-fluoro-2-hydroxyphenyl)-2-furanyl)methylene)-, (5z)-
NCGC00260842-01
tox21_500157
SCHEMBL1494573
5-[1-[5-(4-fluoro-2-hydroxy-phenyl)-furan-2-yl]-meth-(z)-ylidene]-thiazolidine-2,4-dione
AC-32789
AKOS024457740
HMS3650K14
J-516047
EX-A473
mfcd12024675
(5z)-5-[[5-(4-fluoro-2-hydroxyphenyl)-2-furanyl]methylene]-2,4-thiazolidinedione
SW219311-1
NCGC00185997-05
(5z)-5-[[5-(4-fluoro-2-hydroxyphenyl)furan-2-yl]methylidene]-1,3-thiazolidine-2,4-dione
AS-16184
sr-02000000888
SR-02000000888-2
BCP01892
DTXSID801017365
SDCCGSBI-0207184.P002
NCGC00185997-12
Q27263607
compound 26 [pmid: 16789742]
gtpl10578
5-(5-(4-fluoro-2-hydroxyphenyl)furan-2-ylmethylene)thiazolidine-2,4-dione

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Nrf2	Homo sapiens (human)	Potency	23.1093	0.0920	8.2222	23.1093	AID624149
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	21.1923	0.1000	20.8793	79.4328	AID488773; AID588453
ATAD5 protein, partial	Homo sapiens (human)	Potency	17.3512	0.0041	10.8903	31.5287	AID493106; AID493107
USP1 protein, partial	Homo sapiens (human)	Potency	48.6708	0.0316	37.5844	354.8130	AID504865; AID540327
GLS protein	Homo sapiens (human)	Potency	10.0000	0.3548	7.9355	39.8107	AID624146
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	21.1923	0.5318	15.4358	37.6858	AID504845
Parkin	Homo sapiens (human)	Potency	2.5929	0.8199	14.8306	44.6684	AID720573
arylsulfatase A	Homo sapiens (human)	Potency	13.4591	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	21.1923	0.0355	20.9770	89.1251	AID504332
D(1A) dopamine receptor	Homo sapiens (human)	Potency	11.8143	0.0224	5.9449	22.3872	AID488981; AID488982; AID488983
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	12.5893	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	39.8107	0.0060	26.1688	89.1251	AID488953
flap endonuclease 1	Homo sapiens (human)	Potency	26.6795	0.1337	25.4129	89.1251	AID488816; AID588795
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	26.8545	0.4256	12.0591	28.1838	AID504536
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	37.6858	0.0316	22.3146	100.0000	AID588579
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	29.9349	0.1778	24.7352	79.4328	AID488949
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	31.6228	0.2512	15.8432	39.8107	AID504327
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	42.5615	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)	IC50 (µMol)	20.0000	0.0001	0.3371	7.3000	AID266957
Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0010	0.3419	1.3000	AID267039
Casein kinase II subunit alpha'	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0003	1.4320	10.0000	AID267038
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	IC50 (µMol)	0.9400	0.0000	0.7340	10.0000	AID266954
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)	IC50 (µMol)	20.0000	0.0002	0.5953	10.0000	AID266956
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)	IC50 (µMol)	0.0310	0.0003	0.6607	10.0000	AID1185177; AID266953; AID630521
Casein kinase II subunit beta	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0003	1.4875	10.0000	AID267038
Casein kinase II subunit alpha	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0005	1.3332	10.0000	AID267038
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of cytokine production	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
adaptive immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
respiratory burst involved in defense response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
protein phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
neutrophil chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of neutrophil apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell degranulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
innate immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
neutrophil extravasation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of epithelial tube formation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
apoptotic process	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
response to osmotic stress	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
signal transduction	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
JNK cascade	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
response to heat	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
response to UV	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
response to wounding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
response to tumor necrosis factor	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of JUN kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of DNA-templated transcription	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of JNK cascade	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
stress-activated MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of telomerase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
cellular response to lipopolysaccharide	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
cellular response to interleukin-1	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
cellular senescence	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of telomere capping	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
regulation of motor neuron apoptotic process	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
double-strand break repair	Casein kinase II subunit alpha'	Homo sapiens (human)
apoptotic process	Casein kinase II subunit alpha'	Homo sapiens (human)
spermatogenesis	Casein kinase II subunit alpha'	Homo sapiens (human)
Wnt signaling pathway	Casein kinase II subunit alpha'	Homo sapiens (human)
cerebral cortex development	Casein kinase II subunit alpha'	Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase II subunit alpha'	Homo sapiens (human)
liver regeneration	Casein kinase II subunit alpha'	Homo sapiens (human)
regulation of mitophagy	Casein kinase II subunit alpha'	Homo sapiens (human)
positive regulation of protein targeting to mitochondrion	Casein kinase II subunit alpha'	Homo sapiens (human)
regulation of chromosome separation	Casein kinase II subunit alpha'	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Casein kinase II subunit alpha'	Homo sapiens (human)
peptidyl-threonine phosphorylation	Casein kinase II subunit alpha'	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase II subunit alpha'	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
liver development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of protein phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
vasculature development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
glucose metabolic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phagocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of lamellipodium assembly	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to muscle inactivity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of macroautophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
actin cytoskeleton organization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
platelet activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of actin filament depolymerization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
T cell costimulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of TOR signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to insulin stimulus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to muscle stretch	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of multicellular organism growth	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to L-leucine	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
anoikis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of cellular respiration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of neuron apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
T cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
relaxation of cardiac muscle	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cardiac muscle contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
adipose tissue development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to glucose stimulus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to hydrostatic pressure	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to dexamethasone	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cardiac muscle cell contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
energy homeostasis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of actin filament organization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
autosome genomic imprinting	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to butyrate	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of protein localization to membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of fibroblast apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of anoikis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of cell-matrix adhesion	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
endothelial cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
response to ischemia	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
intracellular calcium ion homeostasis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
autophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion molecules	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of autophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
platelet activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of neutrophil apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of Rac protein signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
embryonic cleavage	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of MAPK cascade	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
angiogenesis involved in wound healing	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
platelet aggregation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of sprouting angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
regulation of clathrin-dependent endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of cytokine production	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
adaptive immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
dendritic cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of acute inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
respiratory burst involved in defense response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of triglyceride catabolic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
neutrophil chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
secretory granule localization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of cell adhesion mediated by integrin	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of Rac protein signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
natural killer cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
mast cell degranulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of MAP kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
innate immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of cardiac muscle contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
platelet aggregation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cellular response to cAMP	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
neutrophil extravasation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
hepatocyte apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of calcium ion transmembrane transport	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of fibroblast apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
signal transduction	Casein kinase II subunit beta	Homo sapiens (human)
negative regulation of cell population proliferation	Casein kinase II subunit beta	Homo sapiens (human)
Wnt signaling pathway	Casein kinase II subunit beta	Homo sapiens (human)
peptidyl-threonine phosphorylation	Casein kinase II subunit beta	Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase II subunit beta	Homo sapiens (human)
positive regulation of activin receptor signaling pathway	Casein kinase II subunit beta	Homo sapiens (human)
adiponectin-activated signaling pathway	Casein kinase II subunit beta	Homo sapiens (human)
negative regulation of blood vessel endothelial cell migration	Casein kinase II subunit beta	Homo sapiens (human)
regulation of DNA binding	Casein kinase II subunit beta	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	Casein kinase II subunit beta	Homo sapiens (human)
endothelial tube morphogenesis	Casein kinase II subunit beta	Homo sapiens (human)
protein-containing complex assembly	Casein kinase II subunit beta	Homo sapiens (human)
symbiont-mediated disruption of host cell PML body	Casein kinase II subunit beta	Homo sapiens (human)
negative regulation of viral life cycle	Casein kinase II subunit beta	Homo sapiens (human)
double-strand break repair	Casein kinase II subunit alpha	Homo sapiens (human)
protein phosphorylation	Casein kinase II subunit alpha	Homo sapiens (human)
apoptotic process	Casein kinase II subunit alpha	Homo sapiens (human)
DNA damage response	Casein kinase II subunit alpha	Homo sapiens (human)
signal transduction	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of cell population proliferation	Casein kinase II subunit alpha	Homo sapiens (human)
Wnt signaling pathway	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of translation	Casein kinase II subunit alpha	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase II subunit alpha	Homo sapiens (human)
peptidyl-threonine phosphorylation	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of Wnt signaling pathway	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of cell growth	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of protein catabolic process	Casein kinase II subunit alpha	Homo sapiens (human)
rhythmic process	Casein kinase II subunit alpha	Homo sapiens (human)
protein stabilization	Casein kinase II subunit alpha	Homo sapiens (human)
chaperone-mediated protein folding	Casein kinase II subunit alpha	Homo sapiens (human)
symbiont-mediated disruption of host cell PML body	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of aggrephagy	Casein kinase II subunit alpha	Homo sapiens (human)
regulation of chromosome separation	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Casein kinase II subunit alpha	Homo sapiens (human)
regulation of cell cycle	Casein kinase II subunit alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
magnesium ion binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
MAP kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
MAP kinase kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
ATP binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
JUN kinase kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
enzyme binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein kinase binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein phosphatase binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein serine kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
molecular function activator activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit alpha'	Homo sapiens (human)
protein binding	Casein kinase II subunit alpha'	Homo sapiens (human)
ATP binding	Casein kinase II subunit alpha'	Homo sapiens (human)
protein serine kinase activity	Casein kinase II subunit alpha'	Homo sapiens (human)
protein serine/threonine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein kinase activator activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
protein kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein serine/threonine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
identical protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
ephrin receptor binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit beta	Homo sapiens (human)
chromatin binding	Casein kinase II subunit beta	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit beta	Homo sapiens (human)
signaling receptor binding	Casein kinase II subunit beta	Homo sapiens (human)
protein binding	Casein kinase II subunit beta	Homo sapiens (human)
protein kinase regulator activity	Casein kinase II subunit beta	Homo sapiens (human)
protein domain specific binding	Casein kinase II subunit beta	Homo sapiens (human)
protein-macromolecule adaptor activity	Casein kinase II subunit beta	Homo sapiens (human)
identical protein binding	Casein kinase II subunit beta	Homo sapiens (human)
metal ion binding	Casein kinase II subunit beta	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Casein kinase II subunit beta	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
ATP binding	Casein kinase II subunit alpha	Homo sapiens (human)
kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
identical protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
Hsp90 protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
protein serine kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
nucleus	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
cytoplasm	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
cytosol	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
PcG protein complex	Casein kinase II subunit alpha'	Homo sapiens (human)
acrosomal vesicle	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit alpha'	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha'	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit alpha'	Homo sapiens (human)
chromatin	Casein kinase II subunit alpha'	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha'	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
intercalated disc	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
lamellipodium	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
perinuclear region of cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IB	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
nucleus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
nucleolus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
midbody	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
intracellular membrane-bounded organelle	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IB	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
plasma membrane	Casein kinase II subunit beta	Homo sapiens (human)
PcG protein complex	Casein kinase II subunit beta	Homo sapiens (human)
PML body	Casein kinase II subunit beta	Homo sapiens (human)
extracellular region	Casein kinase II subunit beta	Homo sapiens (human)
nucleus	Casein kinase II subunit beta	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit beta	Homo sapiens (human)
cytoplasm	Casein kinase II subunit beta	Homo sapiens (human)
cytosol	Casein kinase II subunit beta	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit beta	Homo sapiens (human)
secretory granule lumen	Casein kinase II subunit beta	Homo sapiens (human)
extracellular exosome	Casein kinase II subunit beta	Homo sapiens (human)
ficolin-1-rich granule lumen	Casein kinase II subunit beta	Homo sapiens (human)
chromatin	Casein kinase II subunit beta	Homo sapiens (human)
cytoplasm	Casein kinase II subunit beta	Homo sapiens (human)
PcG protein complex	Casein kinase II subunit alpha	Homo sapiens (human)
PML body	Casein kinase II subunit alpha	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit alpha	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha	Homo sapiens (human)
plasma membrane	Casein kinase II subunit alpha	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit alpha	Homo sapiens (human)
Sin3-type complex	Casein kinase II subunit alpha	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (137)

Assay ID	Title	Year	Journal	Article
AID1347163	384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164	384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID266977	Residual activity at human c-RAF at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID1185177	Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
AID267034	Residual activity at human TrkB at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266984	Residual activity at human GSK3alpha at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266986	Residual activity at human IGF1R at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267019	Residual activity at human PKCmu at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266954	Inhibition of human PI3Kalpha	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267035	Inhibition of human Yes at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266964	Residual activity at rat CaMK2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267040	Inhibition of C5a-mediated PKB/Akt phosphorylation in mouse Raw264 macrophage	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266987	Residual activity at human IKKalpha at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267049	AUC in rat at 10 mg/kg, iv	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267016	Residual activity at human PKCepsilon at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267048	Clearance in rat at 10 mg/kg, iv	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267052	Cmax in rat at 10 mg/kg, po	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266963	Residual activity at human Bmx at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267032	Residual activity at human SGK at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266962	Residual activity at mouse Blk at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266998	Residual activity at mouse MKK4 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266973	Residual activity at human Chk1 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266999	Residual activity at human MKK6 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267010	Residual activity at human PKBbeta at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267013	Residual activity at human PKCbeta2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267008	Residual activity at human PKA at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267050	AUC in rat at 10 mg/kg, po	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266982	Residual activity at human Flt3 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267027	Residual activity at human Rsk3 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266994	Residual activity at human Lyn at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266972	Residual activity at human CDK7/CyclinH/MAT1 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266967	Residual activity at human CDK2/CyclinA at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267006	Residual activity at human PDK1 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267043	Inhibition of MCP1-induced PKB/Akt phosphorylation in THP1 cells	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266959	Residual activity at mouse Arg at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267041	Inhibition of SCF-induced PKB/Akt phosphorylation in mouse mast cells at 10 uM	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267004	Residual activity at human PDGFRalpha at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266992	Residual activity at human JNK3 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267005	Residual activity at human PDGFRbeta at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267054	Half life in rat at 10 mg/kg, po	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267058	Dissociation constant, pKa of the compound	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267014	Residual activity at human PKCgamma at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267000	Residual activity at human MKK7-beta at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266961	Residual activity at human Axl at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267033	Residual activity at human Syk at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266956	Inhibition of human PI3Kbeta	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267026	Residual activity at human Rsk2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266996	Residual activity at human MAPKAPK2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266991	Residual activity at human JNK2-alpha-2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267003	Residual activity at human PAK2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266974	Residual activity at human Chk2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267038	Inhibition of human CK2	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266985	Residual activity at human GSK3-beta at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266957	Inhibition of human PI3Kdelta	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267002	Residual activity at human p70S6K at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266970	Residual activity at human CDK5/p35 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267046	Inhibition of MCP1-induced chemotaxis of mouse primary monocytes	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266990	Residual activity at human JNK1alpha1 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267018	Residual activity at human PKCiota at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267020	Residual activity at human PKCtheta at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267011	Residual activity at human PKBgamma at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267036	Residual activity at human ZAP70 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267024	Residual activity at human ROCK2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266988	Residual activity at human IKK-beta at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267055	Volume of distribution in rat at 10 mg/kg, iv	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266976	Residual activity at human CK2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267025	Residual activity at human Rsk1 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266966	Residual activity at human CDK1/CyclinB at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267053	Half life in rat at 10 mg/kg, iv	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266997	Residual activity at human MEK1 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267044	Inhibition of SCF1-induced PKB/Akt phosphorylation in THP1 cells	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266968	Residual activity at human CDK2/CyclinE at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267051	Cmax in rat at 10 mg/kg, iv	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267030	Residual activity at human SAPK3 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267047	Reduction of neutrophil recruitment in mouse at 10 mg/kg, po	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267007	Residual activity at human PI3Kgamma at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266995	Residual activity at human MAPK1 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267028	Residual activity at human SAPK2a at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267056	Metabolism in rat microsome after 1 hr	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267029	Residual activity at human SAPK2b at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266953	Inhibition of human PI3Kgamma	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266978	Residual activity at human CSK at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID1849031	Activation of BMP signaling in HEK293T cells expressing BRE-Vent2 luciferase reporter gene assessed as BRE activation by measuring increase in luciferase activity measured after 22 hrs in the presence of BMP-4 by dual-luciferase assay	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Phenotypic Discovery of Triazolo[1,5-
AID266981	Residual activity at human FGFR3 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266969	Residual activity at human CDK3/CyclinE at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267045	Inhibition of MCP1-induced chemotaxis of THP1 cells	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267017	Residual activity at human PKCeta at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267021	Residual activity at human PKD2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267001	Residual activity at human MSK1 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266971	Residual activity at human CDK6/CyclinD3 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267037	Residual activity at human Abl at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267022	Residual activity at human PRAK at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267012	Residual activity at human PKCalpha at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266979	Residual activity at human cSRC at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266980	Residual activity at human Fes at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267015	Residual activity at human PKCdelta at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266989	Residual activity at human IR at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267023	Residual activity at human PRK2 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID630521	Inhibition of recombinant human PI3Kgamma by HTRF assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Fragment based discovery of a novel and selective PI3 kinase inhibitor.
AID267039	Inhibition of human MKK7beta	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267031	Residual activity at human SAPK4 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266960	Residual activity at human Aurora A at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266993	Residual activity at human Lck at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267009	Residual activity at human PKBalpha at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266958	Residual activity at rat AMPK at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266983	Residual activity at human FYN at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266965	Residual activity at human CaMK4 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID267057	Metabolism in human microsome after 1 hr	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID266975	Residual activity at yeast CK1 at 10 uM in presence of 10 uM ATP relative to control	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (7.69)	29.6817
2010's	16 (61.54)	24.3611
2020's	8 (30.77)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	26 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	2.21	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
theophylline [no description available]	2.1	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
caffeine [no description available]	2.1	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
cgs 15943 9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine: non-xanthine triazoloquinazoline adenosine antagonist. CGS 15943 : A member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors.	2.41	1	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	3.03	4	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.07	1	xanthene
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.21	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
thiazoles [no description available]	2.31	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
fura-2 Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.	2.07	1
gallein gallein: do not confuse with gallin; structure. gallein : A xanthene dye that is fluoran carrying four hydroxy substituents at positions 3', 4', 5' and 6'.	2.07	1	2-benzofurans; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; polyphenol; xanthene dye	fluorochrome; G-protein-coupled receptor antagonist; histological dye
wortmannin [no description available]	2.46	2	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
quercetin [no description available]	2.1	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
myricetin [no description available]	2.1	1	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
nu 7026 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source	2.41	1	organic heterotricyclic compound; organooxygen compound
tgx 221 TGX 221: a platelet aggregation inhibitor	2.8	3	pyridopyrimidine
ic 87114 IC 87114: structure in first source	2.21	1	6-aminopurines; biaryl; quinazolines	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zstk474 ZSTK-474 : A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase.	3.39	2	benzimidazoles; morpholines; organofluorine compound; triamino-1,3,5-triazine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
byl719 [no description available]	2.76	2	proline derivative
sr-3029 SR-3029: highly selective casein kinase 1delta/1epsilon inhibitor with potent antiproliferative properties; structure in first source	2.41	1
cgs 15696 CGS 15696: adenosine antagonist; structure given in first source	2.41	1
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.8	3

Condition	Relationship Strength	Studies
Primary Peritonitis [description not available]	2.03	1
Acute Disease Disease having a short and relatively severe course.	2.03	1
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	2.03	1
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1
Contact Dermatitis [description not available]	2.21	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.63	2
Itching [description not available]	2.21	1
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	2.21	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	2.21	1
Congenital Zika Syndrome [description not available]	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Carcinoma, Epidermoid [description not available]	2.31	1
Cancer of Skin [description not available]	2.31	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.31	1
Skin Neoplasms Tumors or cancer of the SKIN.	2.31	1
Benign Neoplasms, Brain [description not available]	2.52	2
Glial Cell Tumors [description not available]	2.21	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.52	2
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.21	1
Innate Inflammatory Response [description not available]	2.1	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.1	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.05	1
Cancer of Pancreas [description not available]	2.05	1
Carcinoma, Ductal, Pancreatic [description not available]	2.05	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.05	1
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	2.05	1
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	2.06	1
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	2.06	1
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	2.99	1
Cancer of Colon [description not available]	2.99	1
B16 Melanoma [description not available]	2.99	1
Experimental Neoplasms [description not available]	2.99	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.99	1
Bladder Cancer [description not available]	2.08	1
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.08	1

as 252424

Description

Cross-References

Synonyms (47)

Protein Targets (26)

Potency Measurements

Inhibition Measurements

Biological Processes (173)

Molecular Functions (30)

Ceullar Components (25)

Bioassays (137)

Research

Studies (26)

Market Indicators

Research Demand Index: 19.48

Study Types

as 252424

Description

Cross-References

Synonyms (47)

Protein Targets (26)

Potency Measurements

Inhibition Measurements

Biological Processes (173)

Molecular Functions (30)

Ceullar Components (25)

Bioassays (137)

Research

Studies (26)

Market Indicators

Research Demand Index: 19.48

Study Types

Related Drugs (21)

Related Conditions (36)